JP2016512818A - テトランドリンファミリーの医薬製剤及び方法 - Google Patents

テトランドリンファミリーの医薬製剤及び方法 Download PDF

Info

Publication number
JP2016512818A
JP2016512818A JP2016500735A JP2016500735A JP2016512818A JP 2016512818 A JP2016512818 A JP 2016512818A JP 2016500735 A JP2016500735 A JP 2016500735A JP 2016500735 A JP2016500735 A JP 2016500735A JP 2016512818 A JP2016512818 A JP 2016512818A
Authority
JP
Japan
Prior art keywords
tetrandrine
family member
pharmaceutical formulation
acid salt
dibasic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016500735A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512818A5 (enExample
Inventor
キャロル、ロン・ディー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CBA Pharma Inc
Original Assignee
CBA Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CBA Pharma Inc filed Critical CBA Pharma Inc
Publication of JP2016512818A publication Critical patent/JP2016512818A/ja
Publication of JP2016512818A5 publication Critical patent/JP2016512818A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016500735A 2013-03-15 2014-03-06 テトランドリンファミリーの医薬製剤及び方法 Pending JP2016512818A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361792849P 2013-03-15 2013-03-15
US61/792,849 2013-03-15
PCT/US2014/021195 WO2014149848A1 (en) 2013-03-15 2014-03-06 Tetrandrine family pharmaceutical formulations and method

Publications (2)

Publication Number Publication Date
JP2016512818A true JP2016512818A (ja) 2016-05-09
JP2016512818A5 JP2016512818A5 (enExample) 2017-04-06

Family

ID=51529969

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016500735A Pending JP2016512818A (ja) 2013-03-15 2014-03-06 テトランドリンファミリーの医薬製剤及び方法

Country Status (7)

Country Link
US (4) US9517234B2 (enExample)
EP (1) EP2968310A4 (enExample)
JP (1) JP2016512818A (enExample)
KR (1) KR20150142691A (enExample)
CN (1) CN105358149A (enExample)
MX (1) MX2015013155A (enExample)
WO (1) WO2014149848A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10576077B2 (en) 2015-03-23 2020-03-03 Southwest Research Institute Pharmaceutical salt forms of Cepharanthine and Tetrandrine
CN107260694A (zh) * 2017-06-14 2017-10-20 广西大海阳光药业有限公司 一种治疗硅肺、风湿痛、关节痛及神经痛的长效新制剂
CN112402419B (zh) * 2019-08-23 2023-12-08 华东理工大学 海兰地嗪或其药学上可接受的盐在糖尿病或糖尿病并发症药物中的应用
CN111675717B (zh) * 2020-06-21 2023-04-07 兰州理工大学 粉防己单体化合物及其提取方法和用途
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用
CN114159438B (zh) * 2021-11-30 2023-07-18 首都医科大学附属北京安定医院 海兰地嗪及其衍生物在制备治疗抑郁症药物中的应用及所制备的抗抑郁药物

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62207216A (ja) * 1986-03-07 1987-09-11 Tsumura Juntendo Inc アンジオテンシンｉ転換酵素阻害剤
JPS62209018A (ja) * 1986-03-08 1987-09-14 Tsumura Juntendo Inc 血液粘度低下剤
JPS63179878A (ja) * 1987-01-22 1988-07-23 Tsumura & Co 新規アルカロイド
JPH02243627A (ja) * 1989-03-16 1990-09-27 Tsumura & Co 狭心症治療薬
JPH0499723A (ja) * 1990-08-17 1992-03-31 Kaken Shiyouyaku Kk ウイルス・ゲノム不活化剤
US6218541B1 (en) * 1999-06-28 2001-04-17 Cba, International, Inc. Method for extracting bisbenzylisoquinolines
JP2003523954A (ja) * 1999-12-08 2003-08-12 ファルマシア コーポレイション 治療効果が迅速に開始されるシクロオキシゲナーゼ−２阻害剤組成物
JP2009545581A (ja) * 2006-08-04 2009-12-24 エイジーアイ・セラピューティクス・リサーチ・リミテッド Ｍｔ１受容体、５ｈｔ２ｂ受容体及びｌ型カルシウムチャンネル活性を有する少なくとも１つの状態の治療方法
JP2011512416A (ja) * 2008-02-20 2011-04-21 ザ・キュレイターズ・オブ・ザ・ユニバーシティー・オブ・ミズーリ オメプラゾール及びランソプラゾールの組合せと緩衝剤を含んでなる組成物とそれを使用する方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4569852A (en) * 1983-08-23 1986-02-11 Warner-Lambert Company Maintenance of flavor intensity in pressed tablets
US5332747A (en) 1989-09-28 1994-07-26 Cancer Biologics Of America, Inc. Method for potentiating primary drugs in treating multidrug resistant parasitic disease cells
US6911454B1 (en) 1989-09-28 2005-06-28 Cancer Biologics Of America, Inc. Method for potentiating primary drugs in treating multidrug resistant disease
US5025020A (en) 1989-09-28 1991-06-18 Cancer Biologics Of America, Inc. Use of tetrandrine and its derivatives to treat malaria
US5192802A (en) * 1991-09-25 1993-03-09 Mcneil-Ppc, Inc. Bioadhesive pharmaceutical carrier
US5627195A (en) * 1995-04-11 1997-05-06 Massachusetts Eye And Ear Infirmary Treatment for ocular inflammation
US20050245559A1 (en) * 2004-01-23 2005-11-03 Koul Hari K Treatment and prevention of prostate cancer
EP2241561A1 (en) 2009-04-16 2010-10-20 Neuron Biopharma, S.A. Neuroprotective, hypocholesterolemic and antiepileptic compound
WO2011056965A1 (en) 2009-11-05 2011-05-12 Cba International, Inc. Method for extracting and purifying bisbenzylisoquinolines
EP2491930A1 (en) 2011-02-25 2012-08-29 Deva Holding Anonim Sirketi Pharmaceutical combination of betahistine and trimetazidine
CN104955330A (zh) * 2012-09-13 2015-09-30 Cba制药有限公司 粉防己碱药物制剂及方法
CN102898433B (zh) * 2012-09-26 2015-04-15 中国医药研究开发中心有限公司 一种汉防己甲素的没食子酸盐、其药物组合物、其制备方法及其用途
JP2015531355A (ja) * 2012-09-28 2015-11-02 ハンジョウ ベンシェン ファーマシューティカル シーオー．， エルティーディー．Ｈａｎｇｚｈｏｕ Ｂｅｎｓｈｅｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． 腫瘍治療のための薬剤組成物及びその適用

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62207216A (ja) * 1986-03-07 1987-09-11 Tsumura Juntendo Inc アンジオテンシンｉ転換酵素阻害剤
JPS62209018A (ja) * 1986-03-08 1987-09-14 Tsumura Juntendo Inc 血液粘度低下剤
JPS63179878A (ja) * 1987-01-22 1988-07-23 Tsumura & Co 新規アルカロイド
JPH02243627A (ja) * 1989-03-16 1990-09-27 Tsumura & Co 狭心症治療薬
JPH0499723A (ja) * 1990-08-17 1992-03-31 Kaken Shiyouyaku Kk ウイルス・ゲノム不活化剤
US6218541B1 (en) * 1999-06-28 2001-04-17 Cba, International, Inc. Method for extracting bisbenzylisoquinolines
JP2003523954A (ja) * 1999-12-08 2003-08-12 ファルマシア コーポレイション 治療効果が迅速に開始されるシクロオキシゲナーゼ−２阻害剤組成物
JP2009545581A (ja) * 2006-08-04 2009-12-24 エイジーアイ・セラピューティクス・リサーチ・リミテッド Ｍｔ１受容体、５ｈｔ２ｂ受容体及びｌ型カルシウムチャンネル活性を有する少なくとも１つの状態の治療方法
JP2011512416A (ja) * 2008-02-20 2011-04-21 ザ・キュレイターズ・オブ・ザ・ユニバーシティー・オブ・ミズーリ オメプラゾール及びランソプラゾールの組合せと緩衝剤を含んでなる組成物とそれを使用する方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J.BIOL.CHEM., vol. 109, JPN6017043859, 1935, pages 681 - 685, ISSN: 0004048529 *

Also Published As

Publication number Publication date
US20180298022A1 (en) 2018-10-18
US10815243B2 (en) 2020-10-27
WO2014149848A1 (en) 2014-09-25
KR20150142691A (ko) 2015-12-22
MX2015013155A (es) 2016-04-04
US20140275137A1 (en) 2014-09-18
US20170050976A1 (en) 2017-02-23
CN105358149A (zh) 2016-02-24
US10023584B2 (en) 2018-07-17
EP2968310A1 (en) 2016-01-20
US9517234B2 (en) 2016-12-13
US20170050975A1 (en) 2017-02-23
EP2968310A4 (en) 2017-01-11

Similar Documents

Publication Publication Date Title
US10815243B2 (en) Tetrandrine family pharmaceutical formulations and method
TWI844786B (zh) 一種藥物組合物及其應用
EP2567690B1 (en) Use of amisulpride for treating chemotherapy-induced nausea and vomiting
KR102303052B1 (ko) Jak 저해제를 포함하는 제약 조성물
ES2639859T3 (es) Inhibidor de la tolerancia analgésica
JP2013543843A (ja) 即時使用可能なケトロラク製剤
JP4705717B2 (ja) 一定の親和性のあるｎｍｄａアンタゴニストの抗うつ剤としての使用
HUP0203121A2 (hu) Szubsztituált benzimidazolokat tartalmazó gyógyszerkészítmény és alkalmazása
JPWO2021093839A5 (enExample)
CN104955330A (zh) 粉防己碱药物制剂及方法
WO2007143895A1 (fr) Solution supersaturée de chlorhydrate de gemcitabine et son procédé de préparation
JP2021091608A (ja) クマリン誘導体を含有する、細胞増殖性疾患の治療又は予防用医薬
CN102302495A (zh) 一种供注射用盐酸托烷司琼药物组合物
RU2646475C2 (ru) Лечение диабета I и II типа
JP2016514142A (ja) 薬物及び栄養補助剤のバイオアベイラビリティを高める方法及び生成物
CN111233877B (zh) 一种加兰他敏帕莫酸盐及其制备方法
KR20210116008A (ko) 사스 코로나바이러스 감염증 치료용 약학 조성물 및 이의 의약 용도
US20140275138A1 (en) Method and products for treating diabetes
TWI814468B (zh) 藥用組合物、其製備方法及用途
JP2016514143A (ja) 薬物及び栄養補助剤の細胞取り込みを高める方法及び生成物
AU2016216578B2 (en) The use of amisulpride as an anti-emetic
CN115089591A (zh) 布立尼布在制备抑制肠道病毒71型嗜神经性病毒药物中的应用
CN101497603B (zh) 含有被烷氧烷胺氧基取代的吡啶的苯并咪唑衍生物
CN104940212A (zh) 地塞米松用于抑制或治疗转移性或耐药性肿瘤的用途
JP2004224747A (ja) 腸疾患治療薬

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20170303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170303

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20170303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181023

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190123

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190604